Reuters logo
BRIEF-Pharnext ‍amends protocol of international pivotal phase 3 trials of PXT3003
September 18, 2017 / 5:04 PM / in 2 months

BRIEF-Pharnext ‍amends protocol of international pivotal phase 3 trials of PXT3003

Sept 18 (Reuters) - PHARNEXT SAS:

* ‍AMENDS PROTOCOL OF INTERNATIONAL PIVOTAL PHASE 3 TRIALS OF PXT3003 FOR CHARCOT-MARIE-TOOTH DISEASE TYPE 1A​

* ‍AMENDMENT TO ADDRESS A STABILITY ISSUE IN HIGH DOSE FORMULATION OF PXT3003​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below